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Introduction
PAPA syndrome (Pyogenic Arthritis, Pyoderma gangreno-
sum, and Acne) is an ultra-rare autosomal dominant, auto-
inflammatory disease associated to mutations in the
PSTPIP1/CD2BP1 gene. The therapeutic approach during
recurrences consists of steroids, while no agreement exists
on the chronic management. Evidences on the use of biolo-
gics are anecdotal and variable results have been reported.
Objectives
To evaluate the long-term response to treatment with IL1
antagonist in six patients affected by PAPA syndrome.
Methods
Six patients (M:F=3:3; 4 pediatric, 1 young adult and
1 adult, mean age 18 years, range 3-50) affected by
PAPA syndrome were enrolled and treated with IL1
blockers (5 patients Anakinra, 1 patient Anakinra fol-
lowed by Canakinumab). Three patients were already
treated with anti-TNFa monoclonal antibodies without
benefit. Data were collected retrospectively (mean
follow-up 26 months, range 4-38). The frequency of
articular and cutaneous flares in the 24 months before
starting therapy where compared to those occurred dur-
ing anti-IL1 regimen. Acute phase reactants (ESR, CRP,
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Table 1
Pt Sex Mutation Main
manifestations
Manifestations in the 24 months
before treatment
N± of flares during follow-up Treatment (dose,
duration)





















3 M E250Q Pyogenic arthritis 7 flares of pyogenic arthritis
(polyarticular)
3 (mild) articular flares Anakinra
1.5 mg/kg/day
(38 months) and low
dose steroid






1 persistent muscular abscess 0 Anakinra
100 mg/day
(26 months)
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SAA) were assessed at the last visit before the study
enrolment and at last follow-up.
Results
All the patients displayed a significant decrease in fre-
quency of disease flares (Table 1) and normalization of
acute phase reactants. Three patients were asymptomatic
during whole follow-up. Patient #5, with a severe and
persistent pyoderma gangrenosum, displayed a partial
response to Anakinra partially due to a poor compliance
to daily s.c. administration. The shift to Canakinumab
lead to a fast and complete resolution of the skin
manifestations.
Conclusions
The long-term use of IL1 blockers is associated to satis-
factory and persistent control of clinical manifestations
and laboratory findings in PAPA syndrome.
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Table 1 (Continued)





















6 articular flares 0 Anakinra
100 mg/day
(4 months)
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